バイオテクノロジーニュース
  • December 15 , 2023

    Harbour BioMed's Wholly-owned Subsidiary Nona Biosciences Enters into a Global License Agreement with Pfizer for HBM9033, an MSLN-Targeted Antibody-Drug Conjugate (ADC)

    詳しく見る
  • December 12 , 2023

    SystImmune and Bristol Myers Squibb Announce a Global Strategic Collaboration Agreement for the Development and Commercialization of BL-B01D1

    詳しく見る
  • December 6 , 2023

    South Africa's Aspen expands reach with $100M buy of Sandoz's Chinese business

    詳しく見る
  • December 1 , 2023

    AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio

    詳しく見る
  • November 29 , 2023

    FDA Investigating Serious Risk of T-cell Malignancy Following BCMA-Directed or CD19-Directed Autologous Chimeric Antigen Receptor (CAR) T cell Immunotherapies

    詳しく見る
  • November 24 , 2023

    China's First NDA for a KRAS G12C Inhibitor: Innovent Announces the National Medical Products Administration of China Has Accepted and Granted Priority Review Designation to the New Drug Application for IBI351

    詳しく見る
  • November 23 , 2023

    Telitacicept (brand name: 泰愛®) formally granted full approval from conditional approval by NMPA for use in combination with conventional therapy in adult patients with active and auto-antibody positive systemic lupus erythematosus

    詳しく見る
  • November 22 , 2023

    Merck seals $610M biobucks deal to acquire preclinical neurodegenerative biotech Caraway

    詳しく見る
  • November 21 , 2023

    Bristol Myers Squibb and 2seventy bio Provide Update on U.S. FDA Review of sBLA for Abecma (idecabtagene vicleucel) in Earlier Lines of Therapy for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma

    詳しく見る
  • November 20 , 2023

    FDA signs off on new uses for Astellas and Pfizer's Xtandi, Merck's Keytruda

    詳しく見る
  • November 18 , 2023

    AstraZeneca's first-in-class FDA approval for Truqap marred by surprise restriction

    詳しく見る
  • November 17 , 2023

    BeiGene Receives European Commission Approval for BRUKINSA® (zanubrutinib) for the Treatment of Relapsed or Refractory Follicular Lymphoma

    詳しく見る
このウェブサイトでは、お客様の利便性を高めるためにクッキーを使用しています。お客様がこれに同意しているものとしますが、ご希望であればオプトアウトすることができます。 さらに詳しく
お問い合わせはこちらからお願いします。 お問い合わせ